Business
OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer
OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline.
About this update from Osr Holdings, Inc.
[{"type":"text","content":"BASEL, Switzerland, March 25, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline.","length":510,"tagName":"p"},{"type":"image","alt":"OSR Holdings logo (PRNewsfoto/OSR Holdings)","displaySize":"","headline":null,"caption":"OSR Holdings logo (PRNewsfoto/OSR Holdings)","className":"","disableSlideshowImg":false,"size":{"original":{"width":334,"height":277,"url":"https://media.zenfs.com/en/prnewswire.com/d1cf26310f8a0d3a1f4f003318d5e702"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cTh6l6BCVhUkYFTe3KonaA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTUzMTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/d1cf26310f8a0d3a1f4f003318d5e702","width":334,"height":277}},"href":"https://mma.prnewswire.com/media/2393302/OSR_Holdings_logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Dr. Höfer joins OSR Holdings from Merck Healthcare, where she led global programs spanning from preclinical to late-stage clinical development. Prior to Merck, she held senior leadership positions at Sandoz Biopharmaceuticals, Priaxon AG, and Medigene AG, playing a key role in advancing therapeutic programs across various modalities, including New Biological Entities (NBEs), New Chemical Entities (NCEs), nucleotides, and viral and cell-based therapies.","length":456,"tagName":"p"},{"type":"text","content":"Regarding her new appointment, Dr. Höfer said "I am honored to join the distinguished team at OSR Holdings and eager to leverage my extensive drug development experience to advance novel therapies across multiple modalities and therapeutic areas. I look forward to collaborating with my colleagues to improve the lives of patients." ","length":342,"tagName":"p"},{"type":"text","content":"Coupled with her extensive industry experience and a PhD in Pharmacology from the University of Newcastle, Dr. Höfer has a strong foundation in clinical pharmacology and translational medicine, ensuring a seamless trans...